• Carrie M Rosenberger, Katherine D Wick, Hanjing Zhuo, Nelson Wu, Yue Chen, Sharookh B Kapadia, Alessander Guimaraes, Diana Chang, David F Choy, Hubert Chen, Melicent Peck, Kathryn M Sullivan, Serena Ke, Alejandra Jauregui, Aleksandra Leligdowicz, Pratik Sinha, Antonio D Gomez, Kirsten N Kangelaris, Kevin Delucchi, Kathleen D Liu, Carolyn S Calfee, Michael A Matthay, and Carolyn M Hendrickson.
• Human Pathophysiology and OMNI Reverse Translation, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. rosenbc4@gene.com.
• Crit Care. 2023 Jun 13; 27 (1): 234234.

AbstractAngiopoietin-2 (Ang-2) is associated with vascular endothelial injury and permeability in the acute respiratory distress syndrome (ARDS) and sepsis. Elevated circulating Ang-2 levels may identify critically ill patients with distinct pathobiology amenable to targeted therapy. We hypothesized that plasma Ang-2 measured shortly after hospitalization among patients with sepsis would be associated with the development of ARDS and poor clinical outcomes. To test this hypothesis, we measured plasma Ang-2 in a cohort of 757 patients with sepsis, including 267 with ARDS, enrolled in the emergency department or early in their ICU course before the COVID-19 pandemic. Multivariable models were used to test the association of Ang-2 with the development of ARDS and 30-day morality. We found that early plasma Ang-2 in sepsis was associated with higher baseline severity of illness, the development of ARDS, and mortality risk. The association between Ang-2 and mortality was strongest among patients with ARDS and sepsis as compared to those with sepsis alone (OR 1.81 vs. 1.52 per log Ang-2 increase). These findings might inform models testing patient risk prediction and strengthen the evidence for Ang-2 as an appealing biomarker for patient selection for novel therapeutic agents to target vascular injury in sepsis and ARDS.© 2023. The Author(s).

8 keywords...

hide…